Nykode Therapeutics AS
5VB
Company Profile
Business description
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
Contact
Gaustadalleen 21
Oslo Research Park
Oslo0349
NORT: +47 22958193
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
59
Stocks News & Analysis
stocks
ASX tech share upgraded following AI contract wins
Strong demand for AI infrastructure drives fair value lift.
stocks
5 star fully franked ASX dividend payer
Investors in cheap ASX share with a narrow moat enjoys a high yield, but there are risks investors should be aware of.
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,953.60 | 67.00 | 0.75% |
| CAC 40 | 8,035.87 | 42.61 | -0.53% |
| DAX 40 | 25,399.21 | 24.79 | 0.10% |
| Dow JONES (US) | 51,349.92 | 131.59 | -0.26% |
| FTSE 100 | 10,636.71 | 48.17 | -0.45% |
| HKSE | 24,513.14 | 10.43 | -0.04% |
| NASDAQ | 26,797.54 | 22.84 | -0.09% |
| Nikkei 225 | 66,595.07 | 1,113.80 | 1.70% |
| NZX 50 Index | 13,823.68 | 140.05 | 1.02% |
| S&P 500 | 7,670.84 | 12.85 | -0.17% |
| S&P/ASX 200 | 8,774.60 | 65.30 | 0.75% |
| SSE Composite Index | 3,840.83 | 10.38 | 0.27% |